Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

IL23R polymorphisms influence phenotype and response to therapy in patients with ulcerative colitis.

Cravo ML, Ferreira PA, Sousa P, Moura-Santos P, Velho S, Tavares L, de Deus JR, Ministro P, Peixe P, Correia LA, Velosa JF, Maio RF, Brito M.

Eur J Gastroenterol Hepatol. 2014 Jan;26(1):26-32. doi: 10.1097/MEG.0000000000000004.

PMID:
24168842
2.

Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis.

Jürgens M, Laubender RP, Hartl F, Weidinger M, Seiderer J, Wagner J, Wetzke M, Beigel F, Pfennig S, Stallhofer J, Schnitzler F, Tillack C, Lohse P, Göke B, Glas J, Ochsenkühn T, Brand S.

Am J Gastroenterol. 2010 Aug;105(8):1811-9. doi: 10.1038/ajg.2010.95. Epub 2010 Mar 2.

PMID:
20197757
3.

Association of single nucleotide polymorphisms of IL23R and IL17 with ulcerative colitis risk in a Chinese Han population.

Yu P, Shen F, Zhang X, Cao R, Zhao X, Liu P, Tu H, Yang X, Shi R, Zhang H.

PLoS One. 2012;7(9):e44380. doi: 10.1371/journal.pone.0044380. Epub 2012 Sep 11.

4.

Novel genetic risk markers for ulcerative colitis in the IL2/IL21 region are in epistasis with IL23R and suggest a common genetic background for ulcerative colitis and celiac disease.

Glas J, Stallhofer J, Ripke S, Wetzke M, Pfennig S, Klein W, Epplen JT, Griga T, Schiemann U, Lacher M, Koletzko S, Folwaczny M, Lohse P, Göke B, Ochsenkühn T, Müller-Myhsok B, Brand S.

Am J Gastroenterol. 2009 Jul;104(7):1737-44. doi: 10.1038/ajg.2009.163. Epub 2009 May 19.

PMID:
19455118
5.

IL23R and IL12B polymorphisms in Spanish IBD patients: no evidence of interaction.

Márquez A, Mendoza JL, Taxonera C, Díaz-Rubio M, De La Concha EG, Urcelay E, Martínez A.

Inflamm Bowel Dis. 2008 Sep;14(9):1192-6. doi: 10.1002/ibd.20463.

PMID:
18383521
6.

Infliximab as a rescue therapy for hospitalized patients with severe ulcerative colitis refractory to systemic corticosteroids.

Yamamoto-Furusho JK, Uzcanga LF.

Dig Surg. 2008;25(5):383-6. doi: 10.1159/000170882. Epub 2008 Nov 13.

PMID:
19005257
7.

[Medical therapy of inflammatory bowel diseases: ulcerative colitis].

Lakatos L, Lakatos PL.

Orv Hetil. 2007 Jun 24;148(25):1163-70. Review. Hungarian.

PMID:
17573252
8.

Clinical and genetic factors predicting response to therapy in patients with Crohn's disease.

Cravo M, Ferreira P, Sousa P, Moura-Santos P, Velho S, Tavares L, Deus JR, Ministro P, da Silva JP, Correia L, Velosa J, Maio R, Brito M.

United European Gastroenterol J. 2014 Feb;2(1):47-56. doi: 10.1177/2050640613519626.

9.

Ulcerative colitis: diagnosis and treatment.

Langan RC, Gotsch PB, Krafczyk MA, Skillinge DD.

Am Fam Physician. 2007 Nov 1;76(9):1323-30. Review. Erratum in: Am Fam Physician. 2008 Apr 15;77(8):1079.

10.

Epistasis between Toll-like receptor-9 polymorphisms and variants in NOD2 and IL23R modulates susceptibility to Crohn's disease.

Török HP, Glas J, Endres I, Tonenchi L, Teshome MY, Wetzke M, Klein W, Lohse P, Ochsenkühn T, Folwaczny M, Göke B, Folwaczny C, Müller-Myhsok B, Brand S.

Am J Gastroenterol. 2009 Jul;104(7):1723-33. doi: 10.1038/ajg.2009.184. Epub 2009 May 19.

PMID:
19455129
11.

Influence of polymorphisms and TNF and IL1β serum concentration on the infliximab response in Crohn's disease and ulcerative colitis.

Lacruz-Guzmán D, Torres-Moreno D, Pedrero F, Romero-Cara P, García-Tercero I, Trujillo-Santos J, Conesa-Zamora P.

Eur J Clin Pharmacol. 2013 Mar;69(3):431-8. doi: 10.1007/s00228-012-1389-0. Epub 2012 Sep 8.

PMID:
22960943
12.

Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus.

Yamamoto S, Nakase H, Matsuura M, Honzawa Y, Masuda S, Inui K, Chiba T.

J Gastroenterol Hepatol. 2010 May;25(5):886-91. doi: 10.1111/j.1440-1746.2009.06206.x.

PMID:
20546441
13.

Long-term outcome of ulcerative colitis in patients who achieve clinical remission with a first course of corticosteroids.

Garcia-Planella E, Mañosa M, Van Domselaar M, Gordillo J, Zabana Y, Cabré E, López San Román A, Domènech E.

Dig Liver Dis. 2012 Mar;44(3):206-10. doi: 10.1016/j.dld.2011.10.004. Epub 2011 Nov 11.

PMID:
22079262
14.

Association of IL23R, TNFRSF1A, and HLA-DRB1*0103 allele variants with inflammatory bowel disease phenotypes in the Finnish population.

Lappalainen M, Halme L, Turunen U, Saavalainen P, Einarsdottir E, Färkkilä M, Kontula K, Paavola-Sakki P.

Inflamm Bowel Dis. 2008 Aug;14(8):1118-24. doi: 10.1002/ibd.20431.

PMID:
18338763
15.

[Infliximab in moderate to severe steroid-dependent or steroid-refractory ulcerative colitis].

Mocciaro F, Orlando A, Scimeca D, Cottone M.

Recenti Prog Med. 2007 Nov;98(11):560-4. Italian.

PMID:
18044405
16.

Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn's disease and analysis of the IL17F p.His161Arg polymorphism in IBD.

Seiderer J, Elben I, Diegelmann J, Glas J, Stallhofer J, Tillack C, Pfennig S, Jürgens M, Schmechel S, Konrad A, Göke B, Ochsenkühn T, Müller-Myhsok B, Lohse P, Brand S.

Inflamm Bowel Dis. 2008 Apr;14(4):437-45.

PMID:
18088064
17.

Infliximab salvage therapy for patients with ulcerative colitis who failed to respond to tacrolimus.

Tsukamoto H, Tanida S, Mizoshita T, Ozeki K, Ebi M, Shimura T, Mori Y, Kataoka H, Kamiya T, Joh T.

Eur J Gastroenterol Hepatol. 2013 Jun;25(6):714-8. doi: 10.1097/MEG.0b013e32835eb999.

PMID:
23411870
18.

Management of acute severe ulcerative colitis.

Doherty GA, Cheifetz AS.

Expert Rev Gastroenterol Hepatol. 2009 Aug;3(4):395-405. doi: 10.1586/egh.09.24. Review.

PMID:
19673626
19.

Variants at the 3p21 locus influence susceptibility and phenotype both in adults and early-onset patients with inflammatory bowel disease.

Latiano A, Palmieri O, Corritore G, Valvano MR, Bossa F, Cucchiara S, Castro M, Riegler G, De Venuto D, D'Incà R, Andriulli A, Annese V.

Inflamm Bowel Dis. 2010 Jul;16(7):1108-17. doi: 10.1002/ibd.21176.

PMID:
20024904
20.

ATG16L1 and IL23 receptor (IL23R) genes are associated with disease susceptibility in Hungarian CD patients.

Lakatos PL, Szamosi T, Szilvasi A, Molnar E, Lakatos L, Kovacs A, Molnar T, Altorjay I, Papp M, Tulassay Z, Miheller P, Papp J, Tordai A, Andrikovics H; Hungarian IBD Study Group.

Dig Liver Dis. 2008 Nov;40(11):867-73. doi: 10.1016/j.dld.2008.03.022. Epub 2008 May 22.

PMID:
18499543
Items per page

Supplemental Content

Write to the Help Desk